AstraZeneca (LSE:AZN) reported nine-month results on 30 October that kept its growth story firmly on track and reconfirmed its 2026 guidance. For income investors, the group remains something of a paradox: a long payment record sits alongside one of the more modest yields on offer from a FTSE 100 heavyweight. The explanation lies in a Business that reinvests heavily in new medicines while paying a Dividend set in US dollars.

The dividend in numbers

As of 7 October 2026, AstraZeneca's annual dividend was 236.2p per share, with the latest payment at 79.5p. That latest figure matches the first interim for 2026, which the company declared at $1.06 or 79.5p and paid on 8 September.

The indicated Yield is 2.0%. The trailing 12-month yield and the Payout Ratio are both recorded as zero, and for a company that clearly pays dividends those entries are a data quirk rather than a real measurement, so neither is meaningful. Investors wanting a guide to dividend cover will need to work from the company's own reported Earnings instead, dividing the Dividend per share by Earnings Per Share to see how many times profit covers the payment.

The same date shows dividend growth of minus 3.8% year on year. On its face that looks like a cut, but it needs careful reading. AstraZeneca reports in US dollars and sets its dividend in that currency, and sterling amounts move with the exchange rate. A decline measured in pounds may therefore reflect currency movements rather than any decision by the board to pay less, although the figures alone cannot prove the cause.

Streaks and policy

AstraZeneca has paid dividends for 33 consecutive years, a substantial record. Its continuous growth count, however, stands at zero, which again is likely to be influenced by how the sterling figures have moved. The company describes its approach as a progressive dividend policy, stating that it intends to maintain or grow the dividend each year, with each annual amount set by reference to its view of long-term earnings prospects.

Payments are normally made twice a year, with the larger portion arriving as the second interim. That helps to explain why the latest 79.5p is only about a third of the annual figure, and it means the larger part of the year's income is still to come for shareholders.

A progressive policy is a different promise from a policy tied rigidly to a percentage of earnings. It signals that the board wants shareholders to see the dividend rise or at least hold, and it lets the company smooth the payment through the ups and downs of its product cycles. The trade-off is that the dividend will not necessarily rise in step with profit in any given year.

Growth is the main event

The third-quarter numbers illustrate why the yield is low. Total Revenue for the nine months reached $46.9 billion, up 8% on a reported basis and 7% at constant exchange rates. Third-quarter revenue of $16.2 billion rose 7% on both measures, with oncology leading the way.

Management reconfirmed its full-year guidance at constant exchange rates: total revenue growth in a mid-to-high single-digit percentage range and core earnings per share growth in a low double-digit percentage range. In other words, the company continues to direct a great deal of its firepower towards R&D and new medicines, and the dividend is only one part of the return it offers shareholders.

Pharmaceutical groups face a particular challenge in that patents on established medicines eventually expire, so they must keep funding development to replace those revenues. That spending takes priority over a larger payout, and it is a major reason that a company of this scale offers a yield well below the market average. For investors in LSE:AZN, the case rests on growth in earnings that allows the dollar dividend to rise over time rather than on a high starting yield.

Constant exchange rates, which the company uses in its guidance, remove the effect of currency movements so that underlying growth can be seen clearly. The small gap between the 8% reported and 7% constant-currency growth for the nine months shows that currency has been a modest tailwind to the dollar figures this year. Core earnings per share, the measure used in guidance, adjusts reported profit for items such as Amortisation and restructuring, and it is the figure most relevant to the long-term progression of the dividend.

What this means for income investors

A 2.0% indicated yield is unlikely to attract those seeking high immediate income, and the sterling-based growth figures are not flattering. On the other hand, a progressive policy, a 33-year payment history and earnings guided to grow at a low double-digit rate provide a backdrop in which the payout in dollars has room to keep rising. Those holding the shares from the UK remain exposed to the dollar-sterling rate, which can add to or subtract from what arrives in their accounts in any given year.

It also helps to separate two ideas that are easily confused. The dividend itself, set in dollars, is a decision of the board. The sterling value that reaches a UK Shareholder is the dollar amount converted at the prevailing rate, and a rising pound reduces it while a falling pound increases it. Over long periods that currency effect tends to be modest relative to dividend growth, but over a single year it can be the dominant influence on the figure.

What to watch

Attention now turns to full-year results, when the board will set the second Interim Dividend and when investors can judge whether the dollar payment has moved higher for 2026. Other points to follow are delivery against core earnings guidance, progress across the oncology portfolio and pipeline, and any further swings in the Exchange Rate that could reshape sterling returns. Delivery of guidance at AstraZeneca (LSE:AZN) will be the clearest indicator of whether the progressive policy can continue to be funded alongside heavy Investment in new medicines.